ATE120644T1 - Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b. - Google Patents

Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.

Info

Publication number
ATE120644T1
ATE120644T1 AT92901354T AT92901354T ATE120644T1 AT E120644 T1 ATE120644 T1 AT E120644T1 AT 92901354 T AT92901354 T AT 92901354T AT 92901354 T AT92901354 T AT 92901354T AT E120644 T1 ATE120644 T1 AT E120644T1
Authority
AT
Austria
Prior art keywords
hepatitis
treatment
oxathiol
nucleosides
analogues
Prior art date
Application number
AT92901354T
Other languages
English (en)
Inventor
Nghe Nguyen-Ba
Bernard Belleau
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE120644(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919100039A external-priority patent/GB9100039D0/en
Priority claimed from GB919109913A external-priority patent/GB9109913D0/en
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Application granted granted Critical
Publication of ATE120644T1 publication Critical patent/ATE120644T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT92901354T 1991-01-03 1992-01-03 Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b. ATE120644T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919100039A GB9100039D0 (en) 1991-01-03 1991-01-03 Medicaments
GB919109913A GB9109913D0 (en) 1991-05-07 1991-05-07 Medicaments

Publications (1)

Publication Number Publication Date
ATE120644T1 true ATE120644T1 (de) 1995-04-15

Family

ID=26298202

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92901354T ATE120644T1 (de) 1991-01-03 1992-01-03 Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.

Country Status (23)

Country Link
US (2) USRE39155E1 (de)
EP (2) EP0494119A1 (de)
JP (1) JP2659863B2 (de)
KR (1) KR0156747B1 (de)
AT (1) ATE120644T1 (de)
AU (1) AU660650B2 (de)
CA (2) CA2254613A1 (de)
CY (1) CY2047B1 (de)
DE (1) DE69201948T2 (de)
DK (1) DK0565549T3 (de)
EE (1) EE02995B1 (de)
ES (1) ES2070628T3 (de)
GE (1) GEP19981482B (de)
GR (1) GR3015694T3 (de)
HK (1) HK159395A (de)
IE (1) IE73642B1 (de)
IL (1) IL100502A (de)
MD (1) MD1224C2 (de)
NO (1) NO180407C (de)
PH (1) PH31397A (de)
TJ (1) TJ249B (de)
TW (1) TW202385B (de)
WO (1) WO1992011852A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
US5932635A (en) * 1991-07-30 1999-08-03 Cytec Technology Corp. Tackified prepreg systems
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
WO1995007086A1 (en) 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
AU3710395A (en) * 1994-10-22 1996-05-15 Chong Kun Dang Corporation Nucleoside derivatives and process for preparing thereof
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6689761B1 (en) 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
DK0831852T3 (da) * 1995-06-07 2007-03-19 Univ Emory Nukleosider med anti-hepatitis B-virusaktivitet
GB9517022D0 (en) * 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
GB9605293D0 (en) * 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments
PL330747A1 (en) 1996-06-25 1999-05-24 Glaxo Group Ltd Vx478, zidovudin, ftc and/or 3tc containing combinations for use in treating hiv infections
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
EP0986375A2 (de) 1997-04-07 2000-03-22 Triangle Pharmaceuticals Inc. Zusammensetzungen enthatend mkc-442 in kombination mit anderen antiviralen mitteln
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
WO2000009531A2 (en) 1998-08-10 2000-02-24 Novirio Pharmaceuticals Limited β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
DE69923338T2 (de) * 1998-11-02 2006-04-06 Gilead Sciences, Inc., Foster City Kombinationstherapie zur behandlung von hepatitis b infektionen
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
IL153020A0 (en) 2000-05-26 2003-06-24 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
KR20040002871A (ko) 2001-03-01 2004-01-07 트라이앵글 파마슈티칼스 인코포레이티드 시스-ｆｔｃ의 다형 및 기타 결정형
BR0312278A (pt) 2002-06-28 2007-06-19 Idenix Cayman Ltd éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
HUE027522T2 (en) 2002-09-13 2016-11-28 Novartis Ag ß-L-2'-Deoxynucleosides for treatment of resistant HBV strains and for combination therapies
BR0316363A (pt) 2002-11-15 2005-10-04 Idenix Cayman Ltd Nucleosìdeos 2'-ramificado e mutação de flaviviridae
EP2319853B1 (de) 2002-12-12 2014-03-12 IDENIX Pharmaceuticals, Inc. Verfahren zur Herstellung von 2 -verzweigten Nucleosiden
CA2634749C (en) 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP2435052B1 (de) 2009-05-27 2015-07-15 Hetero Research Foundation Feste orale lamivudin-darreichgungsformen mit isomalt

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI87783C (fi) * 1985-05-15 1993-02-25 Wellcome Found Foerfarande foer framstaellning av terapeutiskt anvaendbara 2',3'-dideoxinukleosider
CA1327000C (en) * 1987-08-07 1994-02-15 David L.J. Tyrrell Antiviral therapy for hepatitis b
US5039667A (en) * 1987-08-07 1991-08-13 The Governors Of The University Of Alberta Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
JP2578501B2 (ja) * 1989-03-03 1997-02-05 キヤノン株式会社 電子写真用帯電部材
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
WO1990014079A1 (en) * 1989-05-15 1990-11-29 The United States Of America, Represented By The Secretary, United States Department Of Commerce Method of treatment of hepatitis
WO1990014091A1 (en) * 1989-05-15 1990-11-29 The United States Of America, Represented By The Secretary, United States Department Of Commerce Method of treatment of hepatitis
WO1991000282A1 (en) * 1989-06-27 1991-01-10 The Wellcome Foundation Limited Therapeutic nucleosides
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
KR910007655A (ko) * 1989-10-03 1991-05-30 엠. 피. 잭슨 치료용 뉴클레오시드
IE74701B1 (en) * 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
PT95516A (pt) * 1989-10-06 1991-08-14 Wellcome Found Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
AU8864191A (en) * 1990-11-13 1992-06-11 Biochem Pharma Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
EP1808434A3 (de) * 1991-03-06 2008-04-02 Emory University Verwendung von 5-Fluoro-2'-deoxy-3'-thiacytidin zur Behandlung von Hepatitis B
GB9105899D0 (en) * 1991-03-20 1991-05-08 Wellcome Found Therapeutic nucleosides
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments

Also Published As

Publication number Publication date
USRE39155E1 (en) 2006-07-04
IL100502A0 (en) 1992-09-06
US5532246A (en) 1996-07-02
CA2100269A1 (en) 1992-07-04
DE69201948D1 (de) 1995-05-11
IE73642B1 (en) 1997-06-18
CA2254613A1 (en) 1992-07-04
CA2100269C (en) 1999-02-23
KR0156747B1 (en) 1998-11-16
NO180407C (no) 1997-04-16
CY2047B1 (en) 1998-04-30
MD1224C2 (ro) 1999-11-30
PH31397A (en) 1998-10-29
EE02995B1 (et) 1997-06-16
NO932442D0 (no) 1993-07-05
JPH06507150A (ja) 1994-08-11
EP0565549A1 (de) 1993-10-20
TJ249B (en) 1999-12-23
HK159395A (en) 1995-10-20
NO180407B (no) 1997-01-06
MD950086A (ro) 1997-01-31
EP0494119A1 (de) 1992-07-08
IL100502A (en) 1995-12-08
MD1224B2 (en) 1999-05-31
TW202385B (de) 1993-03-21
EP0565549B1 (de) 1995-04-05
GR3015694T3 (en) 1995-07-31
DK0565549T3 (da) 1995-07-03
DE69201948T2 (de) 1995-08-03
IE920004A1 (en) 1992-07-15
GEP19981482B (en) 1998-12-25
NO932442L (no) 1993-08-26
AU1153492A (en) 1992-08-17
WO1992011852A1 (en) 1992-07-23
AU660650B2 (en) 1995-07-06
JP2659863B2 (ja) 1997-09-30
ES2070628T3 (es) 1995-06-01

Similar Documents

Publication Publication Date Title
ATE120644T1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
HUT59109A (en) Process for producing hydroxymethyl-(methylenecyclopentyl)-purines and -pyrimidines, their pharmaceutically acceptable salts and pharmaceutical compositions comprising same
FI870219A0 (fi) Hypoglykemiska tiazolidindioner.
ATE205712T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der angiogenese und angiogene krankheiten
DE3873578D1 (de) Verwendung von tetrahydrobenz(c,d)indol-6-carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
ATE123944T1 (de) Verwendung von trifluormethylphenyl- tetrahydropyridinen zur herstellung von arzneimitteln zur behandlung anxio-depressiver erkrankungen.
TW206970B (de)
NO932517L (no) 5,10-metylentetrahydrofolsyre-syklo-dekstrin-inkulusjonsforbindels er
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
DE3888340D1 (de) Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
ATE123945T1 (de) Verwendung von fluor enthaltenden pyridoncarbonsäure-derivaten zur herstellung eines arzneimittels zur behandlung von hiv infektionen.
ATE135573T1 (de) Verwendung von indazol-methoxyalkansäure zur herstellung eines arzneimittels zur behandlung von autoimmunkrankheiten
ATE159427T1 (de) Anwendung des n-n-butyl-derivates von desoxynojirimycin zur herstellung eines arzneimittels zur inhibierung von hiv-virus
DK0855398T3 (da) Sesquiterpenderivater med antiviral aktivitet
ES2073871T3 (es) Tiazolidin-2,4-dionas en el tratamiento de la hipertension.
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus
DE3777270D1 (de) Verwendung von l-carnitin zur herstellung eines arzneimittels zur behandlung von toxischen effekten, induziert durch die inhalation von halotan und anderen halogen enthaltenden allgemeinen anaesthetika.
ATE81465T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
EEFA Change of the company name
EELA Cancelled due to lapse of time